Pricing Log in Create free account

IN8bio, Inc. (INAB) vs Lexaria Bioscience Corp. (LEXX)

IN8bio, Inc. and Lexaria Bioscience Corp. are both Biotechnology companies. IN8bio, Inc. and Lexaria Bioscience Corp. are of similar size ($8.8M and $8.2M). Across the 10 metrics below, IN8bio, Inc. leads on 5 and Lexaria Bioscience Corp. on 5.

Valuation

Metric INAB LEXX Biotechnology median
P/E n/m n/m 10.60
P/S n/m 13.74 9.40
P/B 0.99 1.71 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 7.18 9.02
Earnings yield (231.18%) (115.99%) (32.88%)
Free cash flow yield (80.81%) (101.10%) (23.13%)

Profitability

Metric INAB LEXX Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (111.11%) (162.60%) (51.96%)
Return on assets (90.80%) (134.20%) (46.06%)
Return on invested capital (2,948.56%) (662.56%) 0.00%

Growth

Metric INAB LEXX Biotechnology median
Revenue growth (TTM) — 9.08% 6.76%
EPS growth (last fiscal year) 74.06% (40.43%) 29.88%
Revenue growth, 5-year CAGR — 17.53% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INAB LEXX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.21 10.60 4.97
Net debt to EBITDA 1.56 0.17 1.01

Dividend

Metric INAB LEXX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric INAB LEXX Biotechnology median
Market cap 8.19m 8.78m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack